Leading Pharma Company in India - Research & Development Centre Leading Pharma Company in India - Research & Development Centre

Research & Development

Focusing on promoting innovation & knowledge
60PhD Holders
60 ANDAs


Our Company has a dedicated R&D center with Three units located in IMT Manesar, Gurugram, Haryana & One in Mumbai for inhalation products Thane, Maharashtra. One unit of this R&D center is recognized by the DSIR, and one unit is in compliance with WHO GMP and has been inspected by the USFDA. We also have two additional R&D centers which are operated through our non-wholly owned Subsidiaries, including the COPMED Research Centre in Dehradun, Uttarakhand and the Mediforce Research Centre at Paonta Sahib, Himachal Pradesh.

As of March 2024, we have made 60 ANDA for abbreviated new drug applications (ANDAs) with the USFDA (including ten Paragraph IV filings), out of which 44 have been approved, In rest of the world markets (ROW) countries. We have filed for 729 drug product, out of which we had received 504 drug product approvals and we have 225 applications pending under review in various jurisdictions. As on March, 24 we have submitted 26 API drug master file (DMFs) in USFDA, out of which we are granted 11 "Adequate letter" and rest are under review. Also we have filed 11 API Cetificate of Suitability (CEPs) in Europe, against which we have received 11 approvals. Further, we have submitted 4 DMFs in Malaysia, 3 DMFs in Australia & Canada 2 DMFs in China, one each in UK. Brazil and Korea.